Characterization of a Powerful High Affinity Antagonist That Inhibits Biological Activities of Human Interleukin-13*

Yasuo Oshima and Raj K. PuriDagger

From the Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, National Institutes of Health, Bethesda, Maryland 20892

Received for publication, November 8, 2000, and in revised form, January 25, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Interleukin-13 (IL-13), a predominantly Th2-derived cytokine, appears to play a central pathological role in asthma, atopic dermatitis, allergic rhinitis, some parasitic infections, and cancer. We hypothesized that an IL-13 antagonist may have profound therapeutic utility in these conditions. We, therefore, mutagenized human IL-13 in which Glu at position 13 was substituted by a Lys residue. This highly purified recombinant IL-13 variant, IL-13E13K, bound with 4-fold higher affinity to the IL-13 receptor than wild-type IL-13 but retained no detectable proliferative activity on the TF-1 hematopoietic cell line. IL-13E13K competitively inhibited IL-13- and IL-4-dependent TF-1 proliferation. It also inhibited IL-13-induced STAT-6 (signal transduction and activator of transducer-6) activation in immune cells and cancer cells and reversed IL-13-induced inhibition of CD14 expression on human primary monocytes. These results demonstrate that high affinity binding and signal generation can be uncoupled efficiently in a ligand receptor interaction. These results also suggest that IL-13E13K may be a useful antagonist for the treatment of allergic, inflammatory, and parasitic diseases or even malignancies in which IL-13 plays a central role.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

IL-131 binds to its plasma membrane receptors on various cell types (1-10). We have reported that IL-13Rs are overexpressed on a variety of human solid cancer cell lines including renal cell carcinoma, AIDS-associated Kaposi's sarcoma, ovarian carcinoma, prostate cancer, and malignant glioma (1-9, 11-16). We have proposed that the IL-13R complex may exist as three different types. Type I IL-13R appears to be composed of IL-4Ralpha , IL-13Ralpha 1, and IL-13Ralpha 2 subunits (2, 5, 8, 14, 17-19). Type II IL-13R is composed of IL-4Ralpha and IL-13Ralpha 1, and this arrangement also forms the Type II IL-4R (2, 5, 8, 14, 17, 18). In type III IL-4R/IL-13R systems, IL-4Ralpha , IL-13Ralpha 1, and IL-2Rgamma subunits are present. Whether IL-4 or IL-13 engage all three subunits simultaneously for signaling is still not known.

IL-13 regulates a variety of functions in immune cells (20-24). It has been shown to play a prominent role in atopic dermatitis (25, 26), allergic rhinitis (27), pulmonary asthma and related lung injury (22, 28, 29), hepatic fibrosis induced by schistosomiasis (30), and susceptibility to Leishmania major infection (31) and malignancies (2, 12, 32, 33). Therefore, it has been hypothesized that blocking the effect of IL-13 can provide therapeutic benefit in these pathological conditions.

Cytokine receptors for hematopoietic growth factors with a four alpha -helix structure exist largely as homodimers or heterodimers (34). For example, receptors for erythropoietin, thrombopoietin, granulocyte colony-stimulating factor, growth hormone, prolactin, and leptin can exist as homodimers (34). In this class of receptors, a single cytokine binds to two identical subunits and causes receptor internalization and signal transduction. Heterodimeric cytokine receptors generally consist of a major cytokine binding subunit and a signaling subunit (or shared subunit) (34). In this class of receptors, signaling subunits are often shared with more than one cytokine. For example, gp130 receptor subunit is shared with receptors for IL-6, IL-11, leukemia inhibitory factor, ciliary neurotrophic factor, cardiotrophin-1, and oncostatin M. IL-2Rgamma subunit is shared by IL-2, IL-4, IL-9, and IL-15 receptors. The common beta -subunit is shared by receptors for IL-3, IL-5, and GM-CSF (34). Similarly, IL-4Ralpha subunit is shared by the IL-4R and IL-13R system (14, 35-37). In heterodimeric receptor systems, usage of intracellular signaling mechanism(s) is generally also shared (34).

One of the difficulties in understanding the interaction between ligand and the shared receptor subunits is that the subunit itself usually binds its ligand with low affinity. To overcome this problem, numerous cytokine antagonists have been generated by site-directed mutagenesis, which has been shown to utilize heterodimeric receptor systems. These mutants have clarified the crucial role of a particular residue in the ligand-receptor interaction. Among them, various antagonistic muteins including mGM-CSF (38, 39), hIL-5 (40), human IL-6 (41, 42), human leukemia inhibitory factor (43, 44), human IL-15 (45), human and murine IL-2, and human IL-4 (46, 47) have been produced. However, no antagonist of murine or human IL-13 has been produced.

To produce an IL-13 antagonist, we created a mutation in the IL-13 molecule. The selection of the residue to be mutated was based on the knowledge of mutants produced for the IL-4 family of lymphokines (e.g. GM-CSF, IL-5, IL-4, and IL-13) (48, 49). When the amino acid sequence of alpha -helix A of these molecules was aligned, a conserved structure was identified. Mutation in one of the Glu residue in the conserved helical structure produced molecules with altered interaction with their receptors, suggesting that this region is critical for ligand-receptor interaction and signal transduction. For example, when Glu-21, located in alpha -helix A of the mGM-CSF molecule, was mutated to Ala, a mGM-CSF with decreased bioactivity was produced. Similarly, when Glu-9, also located in alpha -helix A of the IL-4 molecule, was mutated to Lys (IL-4E9K), a dramatic inhibition in binding to IL-4Ralpha chain was observed (47). When amino acid residues in alpha -helix A of IL-13, IL-4, mGM-CSF, and hIL-5 were aligned, Glu-13 in IL-13 was identified, which is located at the equivalent position in IL-4, mGM-CSF, and hIL-5 (Fig. 1A). In addition, since IL-4 and IL-13 share two receptor chains with each other and Glu-9 in IL-4 molecule has been shown to interact with the IL-4Ralpha chain, we mutagenized Glu to Lys at this position. This molecule, IL-13E13K was then expressed in Escherichia coli, purified, and further characterized. We demonstrate that IL-13E13K has a 4-8-fold higher binding affinity to IL-13R compared with wtIL-13. Interestingly, IL-13E13K inhibited IL-13-induced signal transduction, cell proliferation, and biological activities in many different cell types. We conclude on the basis of these results that IL-13E13K is a novel powerful antagonist that may have many clinical applications.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Sequence-specific oligonucleotide primers were synthesized at Bioserve Biotechnologies (Laurel, MD). The pET based expression vector (Novagen, Madison, WI) was used for construction of mutein clone. Plasmids were amplified in E. coli, DH5alpha (Life Technologies, Inc.), and DNA was extracted using plasmid purification kits (Qiagen, Chatsworth, CA). Restriction endonucleases and DNA ligase were obtained from New England Biolabs (Beverly, MA), Life Technologies, Inc., Panvera (Madison, WI), and Roche Molecular Biochemicals. TF-1 human erythroleukemia cell line was purchased from ATCC (Manassas, VA). PM-RCC renal cell carcinoma cell line was established in our laboratory (50). THP-1, human monocytic cell line, TORY, virus-immortalized B cell, and KSY-1 AIDS-related Kaposi's sarcoma cell line were obtained and maintained as previously described (51).

Construction of Plasmids Encoding IL-13R112D and IL-13E13K-- The mutagenesis of IL-13 gene was performed using cDNA of wtIL-13 (20) as a template. Sense primer 5'-agg aga tat aca tat gtc ccc agg ccc tgt gcc tcc ctc tac agc cct cag gaa gct cat tga gga-3' and antisense primer 5'-taa ttt gcc cga att cag ttg aac cgt ccc tcg cg-3' were used to mutate Glu-13 to Lys and incorporate NdeI and EcoRI restriction enzyme sites at the 5' and 3' termini, respectively. Construction of the expression vector for IL-13R112D was described before (51). After subcloning the PCR products, the fragment was restricted by NdeI and EcoRI and inserted into an expression vector. We confirmed the existence of mutation and restriction sites by sequencing of the plasmid.

Expression and Purification of Recombinant Proteins-- Expression and purification of wtIL-13, IL-13 mutants, and IL-4 was carried out by similar techniques as previously reported (51, 52). wtIL-13, IL-13 mutants, and IL-4 were produced in inclusion bodies.

Cell Proliferation Assays-- Proliferation assays were performed as described previously (51, 53). Briefly, 1 × 104 TF-1 cells/well were cultured in 96-well plates in RPMI with 5% fetal bovine serum. Varying concentrations of wtIL-13 or IL-4 and/or IL-13 mutein were added to the wells, and the cells were cultured for ~2 days. Tritiated thymidine (0.5 µCi) was added to each well 6-12 h before the plates were harvested in a Skatron cell harvester (Skatron, Inc., Sterling, VA). Glass fiber filter mats were counted in a beta  Plate counter (Wallac, Gaithersburg, MD).

IL-13 Receptor Binding Studies-- wtIL-13 was labeled as previously described (2, 51). The specific activity of radiolabeled IL-13 was 26 µCi/µg. The equilibrium binding studies were performed as described elsewhere (2, 51). Briefly, 5 × 105 cells in 100 µl of binding buffer were incubated at 4 °C for 2 h with 125I-IL-13 (200 or 500 pM) in the absence or presence of various concentrations of unlabeled wtIL-13 or IL-13 mutant. Receptor-bound 125I-IL-13 was separated from unbound 125I-IL-13. The cell pellets were counted in a gamma  counter (Wallac).

Electrophoretic Mobility Shift Assay-- EMSA was performed as described before (7, 18, 51). After incubation with various concentrations of wtIL-13 or IL-13 mutants for 15 min, THP-1 cells, Ebstein-Barr virus-immortalized B cells, or KSY-1 cells were washed with cold phosphate-buffered saline and solubilized with cold whole-cell extraction buffer (1 mM MgCl2, 20 mM HEPES, pH 7.0, 10 mM KCl, 300 mM NaCl, 0.5 mM dithiothreitol, 0.1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, and 20% glycerol). DNA-protein interactions were assessed by electrophoretic mobility shift assay using the Bandshift kit (Amersham Pharmacia Biotech) using the 32P-labeled double-stranded oligonucleotide probe (4.2 × 109 cpm/µg) SBE-1.

CD14 Regulation by IL-13-- Primary monocytes were cultured at 1 × 107 cells/ml for 48 h with 1 ng/ml wtIL-13 with or without 1 µg/ml IL-13E13K. Staining of the cells was performed as described elsewhere (51). The fluorescence data were collected on a FACScan/C32 (Becton Dickinson, San Jose, CA). The results were analyzed with the CELLQuest (Becton Dickinson) program.

Protein Synthesis Inhibition Assay-- Protein synthesis inhibition assay was performed as previously described (3, 51). In brief, 1 × 103 PM-RCC or U251 cells/well were cultured with various concentrations of IL-13PE38QQR incubated for 20-24 h at 37 °C, and then 1 µCi of [3H]leucine (PerkinElmer Life Sciences) was added to each well and cultured for an additional 4 h. For blocking experiments, wtIL-13 or IL-13 mutants and IL-13PE38QQR were added simultaneously. Finally, cells were washed and harvested on a fiberglass filtermat, and cell associated radioactivity was measured in a beta  Plate counter (Wallac). The concentration of IL-13PE38QQR at which 50% inhibition of protein synthesis (IC50) occurred was calculated.

Sequence Alignment and Molecular Modeling of IL-13 Receptor CRH Domain and IL-13-- The sequence of CRH domains of various cytokines were aligned by the Bestfit program of GCG software (Genetics Computer Group, Inc., Madison, WI). Helical wheel analyses were also performed using GCG software. Percent similarity and identity of extracellular domains between IL-13Ralpha 1 and IL-2Rgamma subunits were 40.5 and 31.9%, respectively. These numbers indicate reasonable sequence similarity justifying the use of IL-2Rgamma subunit as a template for modeling IL-13Ralpha 1 subunit. Conserved sequence patterns such as the WSXWS motif and four conserved Cys residues between beta -strands of IL-13Ralpha 1 and IL-2Rgamma were perfectly aligned. The alignment of sequences between IL-4 and IL-13 was also performed as previously reported (20, 54). The similarity and identity of alpha -helix A and D of IL-13 to the known structure of IL-4 was in a similar range, as observed for IL-2Rgamma and IL-13Ralpha 1 subunits. However, the similarity of alpha -helix B and C could not be reasonably determined (54).

The coordinate of the CRH domain of the IL-4Ralpha subunit was also used in our model that was obtained from protein data bank entry 1ILL. The model building and refinement procedures were based on the procedure previously described in detail (55). An initial model was built using the homology module of InsightII (Molecular Simulations Inc., San Diego, CA). Small loops and splices were created and handled such that the energy was kept at minimum for best model. The structures were finally refined using the Discover program (Molecular Simulations Inc., San Diego, CA).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Sequence Alignment of alpha -Helix A between IL-13, IL-4, mGM-CSF. and hIL-5-- When the alpha -helix A of hIL-13, hIL-4, mGM-CSF, and hIL-5 were aligned, glutamic acid residues were found to be aligned perfectly in all of these molecules. In IL-13, this Glu was located at position 13 (Fig. 1A). Helical wheel analysis of IL-13, IL-4, and mGM-CSF suggested that hydrophobic residues clustered in one side of the alpha -helix (Fig. 1B). These hydrophobic residues may be buried in the core of the molecules, as shown for IL-4 and hGM-CSF (56, 57). alpha -Helix A of hIL-5 did not show a cluster of hydrophobic residues (data not shown). Further pattern analysis demonstrated that the aligned critical residues are located in the other side of the hydrophobic buried cluster. Based on these analyses and the fact that Glu in IL-4 and mGM-CSF interact with shared receptor subunits, it is predicted that Glu at position 13 in IL-13 molecule is the "hot residue," and it may also interact with shared receptor subunit.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Prediction of the hot residue in the alpha -helix A of IL-13 molecule. A, alignment of alpha -helices A between mGM-CSF, hIL-5, hIL-4, and hIL-13. Helical residues are in bold. The structurally conserved residues are boxed, whereas consensus buried hydrophobic side chains are shown in reverse (white characters in black box). *, marked Glu of mGM-CSF, hIL-5, and hIL-4 were reported to interact with shared receptor subunits. B, aligned alpha -helices of hIL-13, hIL-4, and mGM-CSF are also shown in helical wheel projections (1 turn every 3.6 residues). Hydrophobic and buried residues may constitute the inner core and are indicated in a box. The aligned and proposed hot Glu are marked with asterisk (*).

Recombinant Protein Isolation and Purification-- Recombinant wtIL-13, IL-13E13K, and IL-13R112D in which the 112th Arg (R) residue of IL-13 molecule was substituted for Asp (D) were expressed in E. coli and purified from inclusion bodies as previously described (51). After purification, each recombinant protein was analyzed using SDS-polyacrylamide gel electrophoresis and stained with Coomassie Blue. Each protein showed a prominent single band at ~13 kDa with purity of at least 95% (Fig. 2).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 2.   SDS-polyacrylamide gel electrophoresis analysis of purified IL-13 and its mutants. Approximately 500 ng of each purified cytokine was loaded per sample. Proteins were detected using Coomassie Blue stain. M, MultiMarkTM multicolored standard (Novex, San Diego, CA).

IL-13E13K Competes for the Binding of Radiolabeled IL-13-- Binding studies were performed using U251 glioblastoma and PM-RCC renal cell carcinoma cell lines, both of which express type I IL-13 receptors (8). As expected, wtIL-13 displaced specific binding of radiolabeled IL-13 (Fig. 3). Interestingly, IL-13E13K also inhibited binding of 125I-IL-13 (Fig. 3). IL-13E13K was better in displacing 125I-IL-13 binding as compared with wtIL-13. In the experiment shown, the EC50 (concentration causing 50% inhibition of 125I-IL-13 binding) of wtIL-13 and IL-13E13K on U251 cells was ~20 and 2.5 nM, respectively. On PM-RCC, it was ~100 and 25 nM, respectively. Thus, IL-13E13K appeared to show ~4.0-8-fold better binding avidity than wtIL-13 in displacing 125I-IL-13 binding.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3.   Competition for the binding of 125I-IL-13 by wtIL-13 and IL-13E13K. 5 × 105 PM-RCC or U251 cells/tube were incubated with 200 or 500 pM 125I-IL-13, respectively, with various concentrations of unlabeled wtIL-13 or IL-13E13K. Data presented are the total cell-bound 125I-IL-13, with error bars representing the S.D. of duplicate determinations.

IL-13E13K Blocks Proliferative Activity of IL-13 and IL-4-- TF-1 erythroleukemia cells proliferate in response to IL-13 (51). We, therefore, measured proliferative activity of wtIL-13 and IL-13E13K (Fig. 4A) either alone or in combination of both (Fig. 4, B and C). As expected, wtIL-13 stimulated the growth of TF-1 cells in a concentration-dependent manner (51). In contrast, IL-13E13K did not show any proliferative activity (Fig. 4B). This result indicated that inserting a mutation at position 13 completely suppressed its agonistic activity and that the amino acid residue at position 13 seemed essential for the IL-13-induced proliferation of TF-1 cells. To determine the effect of IL-13E13K on wtIL-13 induced proliferation of TF-1 cells, we cultured cells in the presence of 1 µg/ml IL-13E13K and various concentrations of wtIL-13. Interestingly, IL-13E13K blocked the mitogenic activity of wtIL-13 (Fig. 4B). This block of IL-13 mitogenic activity appeared to be concentration-dependent (Fig. 4C). A 100-333-fold excess of IL-13E13K completely neutralized wtIL-13-induced mitogenic activity. Because IL-4 has similar biological activities to IL-13 and receptors for both cytokines share two subunits with other (14, 18), we investigated whether IL-13E13K can also suppress the mitogenic response induced by IL-4. As shown in Fig. 4D, IL-13E13K completely neutralized IL-4-induced mitogenic activity.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Proliferation of TF-1 cells induced by IL-13 or IL-13E13K. A, 10,000 TF-1 cells/well were cultured in the presence or absence of various concentrations of wtIL-13 or IL-13E13K for 52 - 54 h. B, the cells were cultured with or without 1 µg/ml IL-13E13K and various concentrations of wtIL-13 for 52 h. C, the cells were cultured with or without 3 ng/ml wtIL-13 in the presence or absence of 300 ng/ml or 1 µg/ml IL-13E13K. D, the cells were cultured with or without 0.1 ng/ml IL-4 in the presence or absence of 300 ng/ml or 1 µg/ml IL-13E13K. The cell proliferation was determined by the uptake of [3H]thymidine in the dividing cells. Data presented are the percentage of the count without cytokine stimulation and the average of triplicate or quadruplicate samples, with error bars representing the S.D. within a data set. Experiments were repeated several times. E13K, IL-13E13K.

IL-13E13K Can Neutralize the Down-regulation of CD14 Expression by wtIL-13 on Human Primary Monocytes-- IL-13 has been shown to down-regulate CD14 expression on monocytes (23, 51). Therefore, we investigated whether IL-13E13K can nullify the down-regulating activity induced by wtIL-13. As shown in Fig. 5, wtIL-13 suppressed CD14 expression on monocytes, and IL-13E13K completely neutralized the effect of wtIL-13. For example, IL-13 decreased the mean channel number (mean fluorescence intensity) in the gated region from 591 to 492 (p < 0.01). IL-13E13K reversed this effect, and the mean channel number recovered to 600. 


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of IL-13E13K on IL-13-induced down-modulation of CD14 expression on monocytes. Primary elutriated monocytes (1 × 107/tube) were cultured with or without 1 ng/ml wtIL-13 in the presence or absence of 1 µg/ml IL-13E13K for 48 h. Cells were then washed and stained as described under "Experimental Procedures." Gated mean fluorescence intensity (MFI) number is indicated in each panel.

IL-13E13K Blocks Signal Transduction Induced by wtIL-13-- IL-13 has been shown to transduce signal through the Janus kinase and STAT pathways (4, 7, 10, 13, 14, 18, 58, 59). STAT-6 is phosphorylated and activated after IL-13 stimulation, which in turn regulates gene transcription. We therefore tested whether IL-13E13K can block the IL-13-induced signaling. THP-1 and Ebstein-Barr virus-immortalized B cell lines express type II and type III IL-13 receptors, respectively, whereas KSY-1 AIDS-associated Kaposi's sarcoma cells express type I IL-13 receptors. In all cell types, both wtIL-13 and IL-13R112D induced STAT-6 activation in a concentration-dependent manner. IL-13R112D, a potent IL-13 agonist, also induced STAT-6 activation, and it was 5-10-fold better than wtIL-13 as previously reported (51) (Fig. 6A). In sharp contrast, IL-13E13K did not seem to stimulate STAT-6 activation even at very high concentrations (50 ng/ml). Moreover, IL-13E13K blocked wtIL-13-induced STAT-6 activation in the THP-1 cell line (Fig. 6B). 10 ng/ml wtIL-13 appears to stimulate maximal activation of STAT-6; however, in the presence of a 10-fold excess IL-13E13K, STAT-6 activation was moderately suppressed, and a 50-fold excess of IL-13E13K almost completely blocked STAT-6 activation.


View larger version (63K):
[in this window]
[in a new window]
 
Fig. 6.   Activation of STAT-6 by IL-13 or IL-13E13K in various cell lines. TORY, THP-1, or KSY-1 cells were incubated with 0, 1, 10, or 50 ng/ml wtIL-13 or IL-13E13K for 15 min (A) or THP-1 cells were incubated with 0 or 10 ng/ml wtIL-13 or with 10 ng/ml wtIL-13 plus 100 or 500 ng/ml IL-13E13K for 15 min (B). wtIL-13 and IL-13E13K were added simultaneously. Cells were processed, and an electrophoretic mobility shift assay was performed as described under "Experimental Procedures."

IL-13E13K Blocks Cytotoxicity Mediated by IL-13PE38QQR-- We have previously produced a chimeric fusion protein composed of wtIL-13 and a mutated form of Pseudomonas exotoxin (PE38QQR) termed IL-13PE38QQR (1, 3, 6, 9, 11, 15, 17, 60). This cytotoxin is highly cytotoxic to IL-13 receptor-positive tumor cells in vitro and in vivo (1, 3, 6, 9, 11, 15, 17, 60). IL-13PE38QQR mediates cytotoxicity through binding to IL-13R and receptor internalization (3); therefore, IL-13 receptor agonists and antagonists must be able to displace the cytotoxicity of the chimeric fusion toxin. To demonstrate interaction between IL-13E13K and IL-13R, we tested whether IL-13E13K can block the cytotoxicity mediated by IL-13PE38QQR. As shown in Fig. 7A, IL-13PE38QQR mediated cytotoxicity in a concentration-dependent manner, and IL-13, IL-13R112D, or IL-13E13K blocked this cytotoxicity. The blocking of cytotoxicity by IL-13, IL-13R112D, and IL-13E13K was observed in a concentration-dependent manner in both cells studied (Fig. 7B). IL-13E13K appeared to be superior to wtIL-13 in the neutralization of IL-13PE38QQR-induced cytotoxicity.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 7.   Wild-type and mutant IL-13 block the cytotoxic activity of IL-13PE38QQR on U251 and PM-RCC cells. One thousand cells/well were cultured in Leu-free media containing various concentrations of IL-13-cytotoxin (IL-13PE38QQR) and 1 µg/ml wtIL-13 or its muteins (A) or containing 1 ng/ml IL-13PE38QQR with or without various concentration of wtIL-13 or its muteins (B) overnight before the addition of 1 µCi of tritiated Leu. Cells were then incubated for 4 h and harvested, and radioactivity was counted with a beta  counter. The data are the average of quadruplicate determinations, with the error bars representing the S.D. within a data set. Experiments were repeated several times.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this report we describe the production and characterization of a powerful antagonist of IL-13 that was produced by site-directed mutagenesis of an amino acid in the predicted alpha -helix A of the IL-13 molecule. Our results demonstrate conclusively that Glu at position 13 in the IL-13 molecule is of crucial importance for the potency and signal generation. The antagonistic activity of IL-13 mutein IL-13E13K was determined based on (a) 4-8-fold better displacement of 125I-IL-13 binding on cancer cells, (b) the inhibition of wtIL-13-induced proliferation of TF-1 cells, (c) neutralization of wtIL-13-induced down-modulation of CD14 expression in primary monocytes, (d) inhibition of wtIL-13-induced activation of STAT-6 in monocytic cell line, and (e) inhibition of cytotoxicity mediated by IL-13PE38QQR. Thus, the antagonistic activities of IL-13E13K were evident in cells that expressed type I, type II, and type III IL-13 receptors.

Interestingly, IL-13E13K not only suppressed IL-13-induced proliferation of TF-1 cells, it also inhibited IL-4-induced mitogenic response in a dose-dependent manner. These results suggest that IL-13E13K may interact with the IL-4Ralpha subunit that is shared between IL-13R and IL-4R complexes (35-37). In that regard, IL-13E13K is similar to muteins of mGM-CSF and hIL-5. The mGM-CSF antagonist E21A and the hIL-5 antagonist E13Q had mutations at the interface with a shared signaling subunit (38-40). On the other hand, IL-4E9K, in which Glu-9 was substituted by Lys, did not result in an antagonist but was incapable of binding to purified IL-4Ralpha -shared subunit (47). IL-13E13K is different from hIL-6 and hIL-15 antagonists that have mutations at alpha -helix D or near the C terminus of the molecule. These antagonists were found to be very specific and could not suppress bioactivity of the related cytokines that share a signaling subunit, e.g. hIL-6 antagonists termed DFRD, DFFD, and DFLD did not antagonize human oncostatin M or human leukemia inhibitory factor, which share the gp130 subunit (41). Similarly, the antagonist of hIL-15 did not antagonize hIL-2 activity, which shares the IL-2Rgamma subunit with IL-15R (45).

Various studies including the crystal structure of IL-4 and its receptor components demonstrate that IL-4 interacts with IL-4Ralpha and IL-2Rgamma subunits (47, 56). alpha -Helix A of IL-4 molecule interacts with IL-4Ralpha subunit, and alpha -helix D may interact with IL-2Rgamma subunit. Because the conserved residues in the IL-2Rgamma subunit are well aligned with the IL-13Ralpha 1 subunit, we created a model of interaction between the CRH domains of IL-13Ralpha 1, IL-4Ralpha , and IL-13 (Fig. 8). This model was created based on our hypothesis that IL-13 interacts with IL-13Ralpha 1 and IL-4Ralpha subunits simultaneously. The model suggests that the receptor binding interface of the IL-13 molecule is located (at least) in alpha -helix A and D and that alpha -helix D interacts with IL-13Ralpha 1 subunit, and alpha -helix A may interact with IL-4Ralpha subunit. Hot Glu in hIL-5, mGM-CSF, and hIL-4 were proposed to interact with shared receptor subunits (38-40, 46, 47, 61). Our model suggests that the hot Glu in the IL-13 molecule may also interact with the IL-4Ralpha subunit, which is shared between the IL-13/IL-4 receptor system (Fig. 8). Future studies involving a three-dimensional structure of IL-13 and a receptor complex determined by x-ray crystallography will confirm these hypotheses.


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 8.   Predicted model for IL-13 interaction with its receptors. Homology model of the CRH domain of IL-13Ralpha 1, IL-4Ralpha subunits, and IL-13 was created as described under "Experimental Procedures." The three-dimensional model is shown as a ribbon diagram. A and D indicate alpha -helix A and D of the IL-13 molecule, respectively. The figure was prepared using the InsightII program.

The mechanism of antagonistic activity of IL-13 caused by single amino acid substitution is not known. This mutation may cause inappropriate aggregation of receptor subunits or intracellular signaling molecules. Alternatively, a mutation in IL-13 molecule may have created a novel surface in the ligand itself that binds the receptor and alters conformation in a manner incapable of signaling. Future studies will investigate these possibilities.

In conclusion, IL-13E13K is a powerful antagonist that may neutralize the effect of IL-13 in various disease processes such as bronchial asthma, allergic rhinitis, and atopic dermatitis. In addition, since IL-13 is an autocrine growth factor for Hodgkin/Reed-Sternberg tumor cells, it is possible that IL-13E13K may also play a significant role in the therapy of Hodgkin's disease.

    ACKNOWLEDGEMENTS

We thank Dr. Kurt A Brorson (Center for Biologics Evaluation and Research, Food and Drug Administration) for valuable help in modeling studies, Dr. Bharat Joshi for reading this manuscript and providing radiolabeled IL-13, and Pamela Dover and Drs. S. Rafat Husain and Subhash Dhawan for reading this manuscript.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 29 Lincoln Dr., NIH Bldg. 29B, Rm. 2NN10, Bethesda, MD 20892. Tel.: 1-301-827-0471; Fax: 1-301-827-0449; E-mail: puri@cber.fda.gov.

Published, JBC Papers in Press, January 26, 2001, DOI 10.1074/jbc.M010159200

    ABBREVIATIONS

The abbreviations used are: IL, interleukin; IL-13, (human, otherwise noted) interleukin-13; IL-13E13K, human interleukin-13E13K mutein; IL-13R112D, human interleukin-13R112D mutein; wtIL-13, wild-type IL-13; STAT-6, signal transduction and activator of transducer-6; IL-13R, IL-13 receptor(s); IL-4, (human wild-type, otherwise noted in the text) interleukin-4; IL-4R, IL-4 receptor(s); IL-4Ralpha (also known as IL-4Rbeta ), IL-4 receptor alpha  subunit; IL-13Ralpha 1 (also known as IL-13Ralpha '), IL-13 receptor alpha 1 subunit; IL-13Ralpha 2 (also known as IL-13Ralpha ), IL-13 receptor alpha  subunit; IL-2Rgamma , human interleukin-2 receptor gamma  subunit; CRH domain, cytokine receptor homology domain; GM-CSF, granulocyte-macrophage colony-stimulating factor; mGM-CSF, murine; GM-CSF, hGM-CSF, human GM-CSF; hIL-5, human IL-5.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Debinski, W., Obiri, N. I., Powers, S. K., Pastan, I., and Puri, R. K. (1995) Clin. Cancer Res. 1, 1253-1258[Abstract]
2. Obiri, N. I., Debinski, W., Leonard, W. J., and Puri, R. K. (1995) J. Biol. Chem. 270, 8797-8804[Abstract/Free Full Text]
3. Puri, R. K., Leland, P., Obiri, N. I., Husain, S. R., Kreitman, R. J., Haas, G. P., Pastan, I., and Debinski, W. (1996) Blood 87, 4333-4339[Abstract/Free Full Text]
4. Murata, T., Noguchi, P. D., and Puri, R. K. (1996) J. Immunol. 156, 2972-2978[Abstract]
5. Murata, T., Obiri, N. I., Debinski, W., and Puri, R. K. (1997) Biochem. Biophys. Res. Commun. 238, 90-94[CrossRef][Medline] [Order article via Infotrieve]
6. Husain, S. R., Obiri, N. I., Gill, P., Zheng, T., Pastan, I., Debinski, W., and Puri, R. K. (1997) Clin. Cancer Res. 3, 151-156[Abstract]
7. Murata, T., Obiri, N. I., and Puri, R. K. (1997) Int. J. Cancer 70, 230-240[CrossRef][Medline] [Order article via Infotrieve]
8. Obiri, N. I., Leland, P., Murata, T., Debinski, W., and Puri, R. K. (1997) J. Immunol. 158, 756-764[Abstract]
9. Maini, A., Hillman, G., Haas, G. P., Wang, C. Y., Montecillo, E., Hamzavi, F., Pontes, J. E., Leland, P., Pastan, I., Debinski, W., and Puri, R. K. (1997) J. Urol. 158, 948-953[Medline] [Order article via Infotrieve]
10. Murata, T., Husain, S. R., Mohri, H., and Puri, R. K. (1998) Int. Immunol. 10, 1103-1110[Abstract]
11. Debinski, W., Obiri, N. I., Pastan, I., and Puri, R. K. (1995) J. Biol. Chem. 270, 16775-16780[Abstract/Free Full Text]
12. Obiri, N. I., Husain, S. R., Debinski, W., and Puri, R. K. (1996) Clin. Cancer Res. 2, 1743-1749[Abstract]
13. Obiri, N. I., Murata, T., Debinski, W., and Puri, R. K. (1997) J. Biol. Chem. 272, 20251-20258[Abstract/Free Full Text]
14. Murata, T., Obiri, N. I., and Puri, R. K. (1998) Int. J. Mol. Med. 1, 551-557[Medline] [Order article via Infotrieve]
15. Debinski, W., Gibo, D. M., Obiri, N. I., Kealiher, A., and Puri, R. K. (1998) Nat. Biotechnol. 16, 449-453[Medline] [Order article via Infotrieve]
16. Joshi, B. H., Plautz, G. E., and Puri, R. K. (2000) Cancer Res. 60, 1168-1172[Abstract/Free Full Text]
17. Debinski, W., Miner, R., Leland, P., Obiri, N. I., and Puri, R. K. (1996) J. Biol. Chem. 271, 22428-22433[Abstract/Free Full Text]
18. Murata, T., Taguchi, J., and Puri, R. K. (1998) Blood 91, 3884-3891[Abstract/Free Full Text]
19. Aman, M. J., Tayebi, N., Obiri, N. I., Puri, R. K., Modi, W. S., and Leonard, W. J. (1996) J. Biol. Chem. 271, 29265-29270[Abstract/Free Full Text]
20. Minty, A., Chalon, P., Derocq, J. M., Dumont, X., Guillemot, J. C., Kaghad, M., Labit, C., Leplatois, P., Liauzun, P., Miloux, B., Minty, C., Casellas, P., Loison, G., Lupker, J., Shire, D., Ferrara, P., and Caput, D. (1993) Nature 362, 248-250[CrossRef][Medline] [Order article via Infotrieve]
21. McKenzie, A. N. J., Culpepper, J. A., Malefyt, R. D., Briere, F., Punnonen, J., Aversa, G., Sato, A., Dang, W., Cocks, B. G., Menon, S., Devries, J. E., Banchereau, J., and Zurawski, G. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3735-3739[Abstract]
22. Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., and Donaldson, D. D. (1998) Science 282, 2258-2261[Abstract/Free Full Text]
23. Cosentino, G., Soprana, E., Thienes, C. P., Siccardi, A. G., Viale, G., and Vercelli, D. (1995) J. Immunol. 155, 3145-3151[Abstract]
24. Punnonen, J., Aversa, G., Cocks, B. G., McKenzie, A. N. J., Menon, S., Aurawski, G., Malefyt, R. D. W., and Vries, J. E. d. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3730-3734[Abstract]
25. Akdis, M., Akdis, C. A., Weigl, L., Disch, R., and Blaser, K. (1997) J. Immunol. 159, 4611-4619[Abstract]
26. Katagiri, K., Itami, S., Hatano, Y., and Takayasu, S. (1997) Clin. Exp. Immunol. 108, 289-294[CrossRef][Medline] [Order article via Infotrieve]
27. Pawankar, R. U., Okuda, M., Hasegawa, S., Suzuki, K., Yssel, H., Okubo, K., Okumura, K., and Ra, C. S. (1995) Am. J. Respir. Crit. Care Med. 152, 2059-2067[Abstract]
28. Grunig, G., Warnock, M., Wakil, A. E., Venkayya, R., Brombacher, F., Rennick, D. M., Sheppard, D., Mohrs, M., Donaldson, D. D., Locksley, R. M., and Corry, D. B. (1998) Science 282, 2261-2263[Abstract/Free Full Text]
29. Zhou, Z., Homer, R. J., Wang, Z. D., Chen, Q. S., Geba, G. P., Wang, J. M., Zhang, Y., and Elias, J. A. (1999) J. Clin. Invest. 103, 779-788[Abstract/Free Full Text]
30. Chiaramonte, M. G., Donaldson, D. D., Cheever, A. W., and Wynn, T. A. (1999) J. Clin. Invest. 104, 777-785[Abstract/Free Full Text]
31. Matthews, D. J., Emson, C. L., McKenzie, G. J., Jolin, H. E., Blackwell, J. M., and McKenzie, A. N. J. (2000) J. Immunol. 164, 1458-1462[Abstract/Free Full Text]
32. Kapp, U., Yeh, W. C., Patterson, B., Elia, A. J., Kagi, D., Ho, A., Hessel, A., Tipsword, M., Williams, A., Mirtsos, C., Itie, A., Moyle, M., and Mak, T. W. (1999) J. Exp. Med. 189, 1939-1945[Abstract/Free Full Text]
33. Fricker, J. (1999) Mol. Med. Today 5, 463-463[CrossRef]
34. Nicola, N. A., and Hilton, D. J. (1999) Adv. Protein Chem. 52, 1-65
35. Izuhara, K., and Harada, N. (1993) J. Biol. Chem. 268, 13097-13102[Abstract/Free Full Text]
36. Smerz-Bertling, C., and Duschl, A. (1996) J. Biol. Chem. 270, 966-970[Abstract/Free Full Text]
37. Wang, L., Keegan, A., Paul, W., Heidaran, M., Gutkind, J., and Pierce, J. (1992) EMBO J. 11, 4899-4908[Abstract]
38. Altmann, S. W., Patel, N., and Kastelein, R. A. (1995) Growth Factors 12, 251-262[Medline] [Order article via Infotrieve]
39. Altmann, S. W., and Kastelein, R. A. (1995) J. Biol. Chem. 270, 2233-2240[Abstract/Free Full Text]
40. Tavernier, J., Tuypens, T., Verhee, A., Plaetinck, G., Devos, R., Heyden, J. V. D., Guisez, Y., and Oefner, C. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5194-5198[Abstract]
41. Savino, R., Ciapponi, L., Lahm, A., Demartis, A., Cabibbo, A., Toniatti, C., Delmastro, P., Altamura, S., and Ciliberto, G. (1994) EMBO J. 13, 5863-5870[Abstract]
42. Savino, R., Lahm, A., Salvati, A., Ciapponi, L., Sporeno, E., Altamura, S., Paonessa, G., Toniatti, C., and Ciliberto, G. (1994) EMBO J. 13, 1357-1367[Abstract]
43. Hudson, K. R., Vernallis, A. B., and Heath, J. K. (1996) J. Biol. Chem. 271, 11971-11978[Abstract/Free Full Text]
44. Vernallis, A. B., Hudson, K. R., and Heath, J. K. (1997) J. Biol. Chem. 272, 26947-26952[Abstract/Free Full Text]
45. Kim, Y. S., Maslinski, W., Zheng, X. X., Stevens, A. C., Li, X. C., Tesch, G. H., Kelly, V. R., and Strom, T. B. (1998) J. Immunol. 160, 5742-5748[Abstract/Free Full Text]
46. Kruse, N., Tony, H. P., and Sebald, W. (1992) EMBO J. 11, 3237-3244[Abstract]
47. Kruse, N., Shen, B., Arnold, S., Tony, H., Meuller, T., and Sebald, W. (1993) EMBO J. 12, 5121-5129[Abstract]
48. Boulay, J., and Paul, W. (1992) J. Biol. Chem. 267, 20525-20528[Free Full Text]
49. Paul, W. (1991) Blood 77, 1859-1870[Medline] [Order article via Infotrieve]
50. Obiri, N. I., Hillman, G. G., Haas, G. P., Sud, S., and Puri, R. K. (1993) J. Clin. Invest. 91, 88-93[Medline] [Order article via Infotrieve]
51. Oshima, Y., Joshi, B. H., and Puri, R. K. (2000) J. Biol. Chem. 275, 14375-14380[Abstract/Free Full Text]
52. Kreitman, R. J., Puri, R. K., McPhie, P., and Pastan, I. (1995) Cytokine 7, 311-318[CrossRef][Medline] [Order article via Infotrieve]
53. Leland, P., Obiri, N., Aggarwal, B. B., and Puri, R. K. (1995) Oncol. Res. 7, 227-235[Medline] [Order article via Infotrieve]
54. Bamborough, P., Duncan, D., and Richards, W. G. (1994) Protein Eng. 7, 1077-1082[Abstract]
55. Greer, J. (1990) Proteins 7, 317-334[Medline] [Order article via Infotrieve]
56. Hage, T., Sebald, W., and Reinemer, P. (1999) Cell 97, 271-281[Medline] [Order article via Infotrieve]
57. Walter, M., Cook, W., Ealick, S., Nagabhushan, T., Trotta, P., and Bugg, C. (1992) J. Mol. Biol. 224, 1075-1085[Medline] [Order article via Infotrieve]
58. Murata, T., and Puri, R. K. (1997) Cell. Immunol. 175, 33-40[CrossRef][Medline] [Order article via Infotrieve]
59. Murata, T., Noguchi, P. D., and Puri, R. K. (1995) J. Biol. Chem. 270, 30829-30836[Abstract/Free Full Text]
60. Husain, S. R., and Puri, R. K. (2000) Blood 95, 3506-3513[Abstract/Free Full Text]
61. Kruse, N., Lehrnbecher, T., and Sebald, W. (1991) FEBS lett. 286, 58-60[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.